This manuscript reviews the reasons why Integrase inhibitors should now routinely
constitute a part of first line antiretroviral therapy for the treatment of HIV disease. The use of …

Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV)
are the most prevalent deadly chronic viral diseases. HIV is treated by small molecule …

More than a quarter of HIV‐infected individuals registered in Russia live in Siberia. Unlike
Central Russia where HIV‐1 subtype A6 is predominant, in most Siberian regions since …

The human immunodeficiency virus type-1 (HIV-1) is the etiological agent of the acquired
immunodeficiency syndrome (AIDS), a disease highly lethal in the absence of combination …

Objectives To evaluate the sensitivity and specificity of genotypic methods for predicting the
co-receptor usage of subtypes B and non-B HIV-1 primary isolates, using as gold standard …

Introduction. Specific molecular epidemic features of HIV infection in Tyumen Oblast (TO),
Russia, were studied. Methods. The genome sequences encoding HIV‐1 protease‐reverse …

Kemerovo Oblast (KO) has had the highest rate of HIV spread in Russia since 2011. The aim
of this work was to study the genetic variation of HIV-1 in Kemerovo Oblast. Blood was …

HIV-1 entry begins with viral envelope glycoprotein gp120 interacting with host-cell CD4 and
an entry coreceptor (mainly chemokine receptors CCR5 or CXCR4). Inhibitors of particular …

The chemokine coreceptor 5 (CCR5) antagonists are antiretroviral agents with an
extracellular, host-targeted mechanism of action against HIV. Maraviroc, the first-in-class …

The evolution of human immunodeficiency virus type 1 (HIV-1) with respect to co-receptor
utilization has been shown to be relevant to HIV-1 pathogenesis and disease. The CCR5 …